Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Denali Therapeutics (DNLI) Other financing activities (2018)

Denali Therapeutics has reported Other financing activities over the past 1 years, most recently at -$1.3 million for Q4 2018.

Quarterly Other financing activities changed N/A to -$1.3 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was -$1.3 million through Sep 2019, down 196.72% year-over-year, with the annual reading at $324000.0 for FY2025, N/A changed from the prior year.
Other financing activities was -$1.3 million for Q4 2018 at Denali Therapeutics, down from $1.3 million in the prior quarter.
Over five years, Other financing activities peaked at $1.3 million in Q3 2018 and troughed at -$1.3 million in Q4 2018.